An interventional study of Omega-3 polyunsaturated fatty acids and Omega-3 polyunsaturated fatty acids in Depressive Symptoms, sponsored by National Science and Technology Council, Taiwan. Completed at 1 site in Japan. Open to female participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-06-10.
Sponsored by National Science and Technology Council, Taiwan · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing omega-3 fatty acid in Depression — 2 open to participants now, 2 under way, none of them phase 3. omega-3 fatty acid · Depression.
Among the 22 studies testing omega-3 fatty acid in Depression, this one is the 22nd largest by enrollment, is one of 2 that started in 2013, is one of 8 with no phase, and was the 19th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →2 of the 22 studies testing omega-3 fatty acid in Depression are open now, in 2 countries. Recruiting first, the newest first:
Université Catholique de Louvain · Sites in Belgium
Ages 18–70
Nanfang Hospital, Southern Medical University · Sites in China
Ages 18–45 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 20 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 6 · Phase 4 1
First in 2004; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 67 across the 22 interventional studies. Of the 19 that completed or were terminated, 6 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 22 has an industry lead sponsor. The 10 most frequent:
National Science and Technology Council, Taiwan is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
National Science and Technology Council, Taiwan has 3 studies filed under Depression — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing omega-3 fatty acid in Depression, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The present study aims to examine the efficacy and safety of omega-3 polyunsaturated fatty acids for pregnant women with depressive symptoms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1200mg EPA and 600mg DHA daily
Dietary Supplement: Omega-3 polyunsaturated fatty acids
320 mg olive oil and 9.9 mg omega-3 PUFAs
Dietary Supplement: Omega-3 polyunsaturated fatty acids
Also known as: 1200mg EPA and 600mg DHA daily
Also known as: 320 mg olive oil and 9.9 mg omega-3 PUFAs
Total score of the Hamilton Rating Scale for Depression(HAMD)
The Hamilton Rating Scale for Depression (HAMD) is a commonly used clinical tool for assessing the severity of depression. The most frequently used version, the HAMD-17, includes 17 items and has a total score range from 0 to 52. Higher scores indicate more severe depressive symptoms and thus a worse outcome, while lower scores suggest milder symptoms or improvement.
Time frame: Twelve weeks
Total score of the Hamilton Rating Scale for Depression(HAMD)
The Hamilton Rating Scale for Depression (HAMD) is a commonly used clinical tool for assessing the severity of depression. The most frequently used version, the HAMD-17, includes 17 items and has a total score range from 0 to 52. Higher scores indicate more severe depressive symptoms and thus a worse outcome, while lower scores suggest milder symptoms or improvement.
Time frame: 4-6 weeks after childbirth
Total scores on the Edinburgh Postnatal Depression Scale(EPDS)
The Edinburgh Postnatal Depression Scale (EPDS) is a screening tool used to identify symptoms of postpartum depression. It consists of 10 items, each scored from 0 to 3, giving a minimum total score of 0 and a maximum total score of 30. Higher scores indicate more severe depressive symptoms, meaning a worse outcome, while lower scores suggest fewer or milder symptoms.
Time frame: Twelve weeks, 4-6 weeks after childbirth
Total score of the Beck Depression Inventory II (BDI-II)
The Beck Depression Inventory-II (BDI-II) is a widely used self-report questionnaire designed to assess the severity of depressive symptoms. It includes 21 items, each scored from 0 to 3, resulting in a minimum total score of 0 and a maximum total score of 63. Higher scores indicate more severe depression, meaning a worse outcome, while lower scores reflect fewer or less severe symptoms.
Time frame: Twelve weeks, 4-6 weeks after childbirth
Major depressive disorder(MDD)as determined by the depression module of the Mini International Neuropsychiatric Interview (MINI)
Time frame: Twelve weeks, 4-6 weeks after childbirth
Omega-3 fatty acids concentrations in erythrocytes
Time frame: Twelve weeks, 4-6 weeks after childbirth
Brain-derived neurotrophic factor(BDNF)in serum
Time frame: Twelve weeks, 4-6 weeks after childbirth
Estrogen in serum
Time frame: Twelve weeks, 4-6 weeks after childbirth
Oxytocin in serum
Time frame: Twelve weeks, 4-6 weeks after childbirth
Progesterone in serum
Time frame: Twelve weeks, 4-6 weeks after childbirth
Human chorionic gonadotropin (hCG)in serum
Time frame: Twelve weeks, 4-6 weeks after childbirth
Phospholipase A2 in plasma
Time frame: twelve weeks, 4-6 weeks after childbirth
Gestational age
Time frame: 1 month after childbirth
Gestational diabetes mellitus
Time frame: 1 month after childbirth
Gestational hypertension or preeclampsia
Time frame: 1 month after childbirth
Induced labor
Time frame: 1 month after childbirth
Estimated blood loss
Time frame: 1 month after childbirth
Cesarean section
Time frame: 1 month after childbirth
Operative vaginal delivery
Time frame: 1 month after childbirth
Birthweight
Time frame: 1 month after childbirth
1-min and 5-min Apgar scores
Time frame: 1 month after childbirth
Ran from Jan 2013 to primary completion in May 2017, 52 months.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 52 months is above that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Omega-3 fatty acid
National Science and Technology Council, Taiwan